Study identifies non-weight-dependent protection against liver fibrosis

Researchers have identified a mechanism where the hormone GDF15 reduces inflammation and slows tissue scarring (fibrosis) in the liver during steatohepatitis. The study reveals that this protection occurs via a specific neuroendocrine pathway and operates independently of weight loss or changes in liver fat levels. How the protection mechanism works While GDF15 was previously known as an appetite regulator that helps lower body mass, this research uncovered an additional function: the activation of the "brain-liver" signaling axis. This process triggers the release of glucocorticoids—steroid hormones that regulate metabolism and the immune response—through the nervous system. These glucocorticoids act on the liver's immune cells, shifting them into a less active, protective state. This suppresses inflammation and slows the accumulation of scar tissue, which in severe cases leads to cirrhosis and liver failure.